Who Really Benefits from CPAP? Disease Severity, Response Quality, and Long-Term Survival in Obstructive Sleep Apnea
Advances in Respiratory Medicine · 28.07.2026 · 94 (4) · 55
DOI: 10.3390/arm94040055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Respiratory Medicine, online erschienen am 28.07.2026. Verfasst von Wojciech Kuczyński und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Łódź, Poland. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Continuous Positive Airway Pressure. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obstructive sleep apnea (OSA) is associated with increased cardiovascular, respiratory, and all-cause mortality, yet the long-term survival impact of continuous positive airway pressure (CPAP) remains contested, and treatment is usually analysed as a binary exposure rather than by the quality of the response achieved. In a single-centre cohort of 4368 adults referred for polysomnography and followed for 8–20 years (prespecified subgroup with apnea–hypopnea index [AHI] ≥ 15, n = 2304), we applied cause-specific Cox and Fine–Gray competing-risks models, together with machine-learning classifiers, to characterise all-cause, cardiovascular, and pulmonary mortality. CPAP was associated with reduced all-cause (hazard ratio [HR] 0.75), cardiovascular (HR 0.75), and pulmonary mortality (HR 0.54), with the benefit confined to severe OSA (HR 0.66) and absent in moderate disease (HR 0.95). Good responders showed a significant 34% reduction in all-cause mortality (HR 0.66), whereas poor responders showed no significant reduction. Nocturnal desaturation (time with oxygen saturation < 90%) was the dominant independent predictor of pulmonary mortality, and baseline features predicted response category only moderately (macro-averaged AUC 0.76). Long-term CPAP confers a severity- and response-dependent survival benefit; nocturnal hypoxaemia is a key, modifiable driver of respiratory death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Łódź, Poland.
ORCID-Profile: Wojciech Kuczyński, Karol Pierzchała, Weronika Bielska, Zuzanna Boczar
Zitieren
APA
Kuczyński, W., Pierzchała, K., Bielska, W., Boczar, Z., Kudrycka, A., & Białasiewicz, P. (2026). Who Really Benefits from CPAP? Disease Severity, Response Quality, and Long-Term Survival in Obstructive Sleep Apnea. Advances in Respiratory Medicine, 94(4), 55. https://doi.org/10.3390/arm94040055
Vancouver
Kuczyński W, Pierzchała K, Bielska W, Boczar Z, Kudrycka A, Białasiewicz P. Who Really Benefits from CPAP? Disease Severity, Response Quality, and Long-Term Survival in Obstructive Sleep Apnea. Advances in Respiratory Medicine. 2026;94(4):55. doi:10.3390/arm94040055
BibTeX
@article{Kuczyski2026,
author = {Kuczyński, Wojciech and Pierzchała, Karol and Bielska, Weronika and Boczar, Zuzanna and Kudrycka, Aleksandra and Białasiewicz, Piotr},
title = {Who Really Benefits from CPAP? Disease Severity, Response Quality, and Long-Term Survival in Obstructive Sleep Apnea},
journal = {Advances in Respiratory Medicine},
year = {2026},
volume = {94},
number = {4},
pages = {55},
doi = {10.3390/arm94040055}
}
EUVIMED